TPG Growth, the growth capital investment arm of US-based private equity giant TPG, has said it will invest $30 million in Solara Active Pharma, a manufacturer of active pharmaceutical ingredients (API). Solara has a...
Strides to exit Australia, announces acquisitions in North America
Strides Pharma Science Ltd will exit Australia while acquiring a company each in the US and Canada in a major revamp of its international operations. The Bengaluru-based company said its unit, Strides Pharma Global, has...
Here’s Why Bristol-Myers Needs a $74 Billion Shot in the Arm
Bristol-Myers Squibb Co.’s impending $74 billion acquisition of biotechnology giant Celgene Inc. makes it easy to overlook something as relatively prosaic as the firm’s fourth-quarter earnings results Thursday. They...
Aurobindo acquires 7 oncology drugs from spectrum for $300 million
Aurobindo PharmaNSE -1.27 % on Thursday said it has acquired seven marketed oncology injectable products from Spectrum Pharmaceuticals Inc for about $300 million, which includes an upfront cash payment of up to $160...
Indoco in talks to sell part of India operations
Indoco Remedies NSE 0.86 % is in initial discussions with investors such as Zydus Cadila and Lupin, along with private equity funds including TPG Capital Management and Temasek Holdings to sell part of its domestic...
Mexico’s Alpek to purchase PET recycling plant in Indiana
Mexican petrochemical company Alpek (ALPEKA.MX), a unit of conglomerate Alfa (ALFAA.MX), said on Wednesday it had agreed to purchase a PET recycling plant in Richmond, Indiana from Perpetual Recycling Solutions, LLC...
Eli Lilly to buy cancer treatment company Loxo Oncology for $8 bn in cash
Eli Lilly and Co said on Monday it will buy Loxo Oncology Inc for $8 billion, an expensive bet on a pipeline of cancer drugs that target rare genetic mutations and the biggest acquisition in Lilly’s 143-year...
South Korea’s Celltrion aims to set up China JV within first half of 2019: chairman
South Korean drugmaker Celltrion Inc (068270.KS) aims to set up a joint venture in China within the first half of this year, and begin selling products in the country next year, its chairman said on Sunday. “Since last...
Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal
Celgene Corp and Bristol-Myers Squibb Co will have to pay $2.2 billion if either of the drugmakers walks away from their $74 billion merger announced on Thursday, according to a regulatory filing. The deal, which is...
Sun Pharma acquires Japan’s Pola Pharma
Drug major Sun Pharma on Thursday said it has completed acquisition of Japan-based Pola Pharma to strengthen its presence in dermatology segment across the globe. The acquisition of 100% shares of Pola Pharma Inc Japan...
Bristol-Myers Squibb to buy Celgene in $74 billion deal
New York-based pharmaceutical giant Bristol-Myers Squibb Co. on Thursday announced it would buy US biotech firm Celgene Corp. in a $74 billion cash-and-stock deal, instantly creating a rival to the world’s largest drug...
Lupin ties up with US-based AbbVie for cancer drug, to earn $ 1 billion
Lupin on Monday announced a partnership with US-based drug maker AbbVie to develop a novel cancer drug that will potentially earn it over $1 billion in fee, milestone payments and royalties. The firm said the drug...
